Altered Antibody Responses in Persons Infected with HIV-1 While Using Preexposure Prophylaxis
Authors:
- Ivana ParkerIPIvana Parker
- George KhalilGKGeorge Khalil
- Amy MartinAMAmy Martin
- Michael T MartinMMMichael T Martin
- Suphak VanichseniSVSuphak Vanichseni
- Wanna LeelawiwatWLWanna Leelawiwat
- Janet M McNichollJMJanet M McNicholl
- Andrew HickeyAHAndrew Hickey
- J. Gerardo García-LermaJ. Gerardo García-Lerma
- Kachit ChoopanyaKCKachit Choopanya
- Kelly A. CurtisKCKelly A. Curtis
- 1 March 2021
- journal article
- research article
- Published by SAGE Publications in AIDS Research and Human Retroviruses
- Vol. 37 (3) , 189-195
Abstract
Background: Pre-exposure prophylaxis (PrEP) is an effective HIV prevention tool, although effectiveness is dependent upon adherence. It is important to characterize the impact of PrEP on HIV antibody responses in people who experience breakthrough infections in order to understand the potential impact on timely diagnosis and treatment. Methods: Longitudinal HIV-1-specific antibody responses were evaluated in 42 people who inject drugs (PWID) from the Bangkok Tenofovir Study (placebo=28; PrEP=14) who acquired HIV while receiving PrEP. HIV-1 antibody levels and avidity to three envelope proteins (gp41, gp160, and gp120) were measured in the plasma using a customized Bio-Plex (Bio-Rad Laboratories) assay. A survival analysis was performed for each biomarker to compare the distribution of times at which study subjects exceeded the recent/long-term assay threshold, comparing PrEP and placebo treatment groups. We fit mixed-effects models to identify longitudinal differences in antibody levels and avidity between groups. Results: Overall, longitudinal antibody levels and avidity were notably lower in the PrEP breakthrough group compared to the placebo group. Survival analyses demonstrated a difference in time to antibody reactivity between treatment groups for all Bio-Plex biomarkers. Longitudinal gp120 antibody levels within the PrEP breakthrough group were decreased compared to the placebo group. When accounting for PrEP adherence, both gp120 and gp160 antibody levels were lower in the PrEP breakthrough group compared to the placebo group. Conclusion: We demonstrate hindered envelope antibody maturation in PWID who became infected while receiving PrEP in the Bangkok Tenofovir Study, which has significant implications for HIV diagnosis. Delayed maturation of the antibody response to HIV may increase the time to detection for antibody-based tests.Keywords
This publication has 36 references indexed in Scilit:
- Evaluation of a Multiplex Assay for Estimation of HIV-1 IncidencePLOS ONE, 2013
- Development and Characterization of a Bead-Based, Multiplex Assay for Estimation of Recent HIV Type 1 InfectionAIDS Research and Human Retroviruses, 2012
- Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with MenNew England Journal of Medicine, 2010
- The Effects of Early Antiretroviral Therapy and Its Discontinuation on the HIV-Specific Antibody ResponseAIDS Research and Human Retroviruses, 2006
- Seroreversion in Subjects Receiving Antiretroviral Therapy during Acute/Early HIV InfectionClinical Infectious Diseases, 2006
- Development and Validation of an Immunoassay for Identification of Recent Human Immunodeficiency Virus Type 1 Infections and Its Use on Dried Serum SpotsJournal of Clinical Microbiology, 2005
- Incomplete HIV Type 1 Antibody Evolution and Seroreversion in Acutely Infected Individuals Treated with Early Antiretroviral TherapyClinical Infectious Diseases, 2005
- Incomplete Antibody Evolution and Seroreversion after Treatment of Primary HIV Type 1 Infection: What Is the Clinical Significance?Clinical Infectious Diseases, 2005
- Performance of the OraQuick Rapid Antibody Test for Diagnosis of Human Immunodeficiency Virus Type 1 Infection in Patients with Various Levels of Exposure to Highly Active Antiretroviral TherapyJournal of Clinical Microbiology, 2003
- Precision and Accuracy of a Procedure for Detecting Recent Human Immunodeficiency Virus Infections by Calculating the Antibody Avidity Index by an Automated Immunoassay-Based MethodJournal of Clinical Microbiology, 2002